Does Sofosbuvir Interact with Sofosbuvir Velpatasvir And Voxilaprevir?
CDI records a unknown classification for Sofosbuvir and Sofosbuvir Velpatasvir And Voxilaprevir. The stored summary is: John's wort, carbamazepine): May decrease concentrations of sofosbuvir, velpatasvir, and/or voxilaprevir. ( 7.3 ) 7.1 Potential for Other Drugs to Affect VOSEVI Sofosbuvir, velpatasvir, and voxilaprevir are substrates of drug transporters P-gp and BCRP while GS-331007 (predominant circulating metabolite of sofosbuvir) is not. John's wort, carbamazepine) may significantly decrease plasma concentrations of sofosbuvir, velpatasvir, and/or voxilaprevir leading to reduced therapeutic effect of VOSEVI. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Unknown
- Sofosbuvir Class
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
- Sofosbuvir Velpatasvir And Voxilaprevir Class
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
- Management
- Consult your pharmacist
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Sofosbuvir and your doctor is considering prescribing Sofosbuvir Velpatasvir And Voxilaprevir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Never stop or change either medication without first consulting your healthcare provider